Spotlight Poster Discussion 10 – Thursday, December 8, 2022: 7:00 am
   
  Endocrine Therapy and Resistance
PD10-01 Impact of ESR1 mutations on selective estrogen receptor degraders and modulators: An integrated liquid-biopsy and pharmacodynamics approach
Gerratana L, Roncato R, Sturlese M, Davis AA, Velimirovic M, Reduzzi C, Clifton KK, Hensing WL, Shah AN, Dai CS, D'Amico P, Medford AJ, Franzoni A, Cucciniello L, Wehbe F, Wander SA, Belletti B, Gradishar W, Behdad A, Damante G, Ma CX, Puglisi F, Bardia A, Cristofanilli M. Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano; IRCCS CRO Aviano National Cancer Insititute; University of Padova; Washington University in St Louis School of Medicine; MGH Cancer Center; Weill Cornell Medicine; Northwestern University; MGH Cancer Center; Massachusetts General Hospital Cancer Center / Dana Farber Cancer Institute; Institute of Human Genetics, University of Udine; Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano; Massachusetts General Hospital, Harvard Medical School, Boston, MA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, United States; Northwestern University; Institute of Human Genetics, University of Udine; Washington University School of Medicine; Department of Medicine (DAME), University of Udine, Udine, Italy and Department of Medical Oncology - CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy; Massachusetts General Hospital Cancer Center.
PD10-02 Novel ER fusion detection method to gain insight in fusion prevalence and endocrine resistant mechanisms
Yates ME, Liu T, Hooda J, Yang S, Bao R, Atkinson JM, Lee AV, Oesterreich S. University of Pittsburgh; Tsinghua University; Magee-Women Research Institute; Case Western Reserve University; University of Pittsburgh; UPMC Hillman Cancer Center.
PD10-03 Super-enhancer-oriented integrative bioinformatics identifies aberrant KLF4 signaling in endocrine-resistant breast cancer (BC)
Liu CC, Qin L, Sathe S, Nanda S, Veeraraghavan J, Cohen O, Wagle N, Rimawi MF, Osborne CK, Fu X, Schiff R. Baylor College of Medicine, Houston, TX, USA; Broad Institute of MIT and Harvard, Cambridge; Dana-Farber Cancer Institute; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.
PD10-04 Combination of the next generation oral SERD camizestrant (AZD9833) with CDK4/6 and mTOR/AKT inhibitors delivers robust efficacy in a broad range of ER+ breast tumors
Carnevalli L, Ros S, Urosevic J, Cureton N, Darcy S, Lawson M, Williamson S, Morentin Gutierrez P, Bashi A, Moss J, Morrow C, Simon B, Klinowska T. AstraZeneca.
PD10-05 Neoadjuvant tamoxifen therapy reactivates tumor suppressor protein p53 in luminal breast cancer patients: Results from a window-of-opportunity clinical trial
Das GM, Kulkarni SA, Oturkar C, Rosario S, Edge SB, Wang J, Swetzig WM, Hutson AD, Kaipparettu B, Groman A, Adjei A, Goey AK, Morrison CD, Kumar S. Roswell Park Comprehensive Cancer Center; Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA; Baylor College of Medicine.
PD10-06 Clinical outcomes and exploratory gene expression analysis of OPPORTUNE: a phase II window-of-opportunity study to evaluate pictilisib+anastrozole versus anastrozole alone in ER-positive breast cancer
Martinez Chibly A, Shia A, Johnson R, Hwang MS, Hafner M, Metcalfe C, Shah K, Slyper M, Bolen C, Pinder SE, Thompson AM, Gendreau S, Schmid P. Genentech Inc.; Queen Mary, University of London; School of Cancer and Pharmaceutical Sciences, King’s College London Faculty of Life Sciences and Medicine, London; Baylor College of Medicine; Barts Cancer Institute, Queen Mary University of London.
PD10-07 Low plasma estradiol, low expression of estrogen responsive genes and TP53 mutations are associated with poor anti-proliferative response to aromatase inhibitors
Schuster EF, López-Knowles E, Alataki A, Zabaglo L, Folkerd E, Evans D, Sidhu K, Tovey H, Maxwell P, Turner NC, Johnston S, Salto-Tellez M Cheang MCU, Robertson J, Smith I, Bliss J, Dowsett M. Breast Cancer Research, The Institute of Cancer Research, London; Royal Marsden NHS Foundation Trust; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London; School of Medicine, Dentistry and Biomedical Sciences Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast; The Royal Marsden NHS Foundation Trust; The Institute of Cancer Research, London; The Institute of Cancer Research, London; Queen's University Belfast, Belfast; University of Nottingham, Nottingham, UK; University Hospitals of Derby and Burton, Derby, UK.
PD10-08 Immune cell infiltration associated with poor anti-proliferative response to aromatase inhibitors in postmenopausal women with primary ER-positive HER2-negative breast cancer
Alataki A, Schuster G, Zabaglo L, Maxwell P, López-Knowles E, Folkerd E, Evans D, Sidhu K, Tovey H, Turner NC, Johnston S, Cheang MCU, Robertson J, Salto-Tellez M, Smith I, Bliss J, Dowsett M. Breast Cancer Research, The Institute of Cancer Research, London; School of Medicine, Dentistry and Biomedical Sciences Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast; Royal Marsden NHS Foundation Trust; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London; The Royal Marsden NHS Foundation Trust; The Institute of Cancer Research, London; University of Nottingham, Nottingham, UK; University Hospitals of Derby and Burton, Derby, UK; The Institute of Cancer Research, London; Queen's University Belfast, Belfast; The Royal Marsden NHS Foundation Trust, London; The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK.
PD10-09 Multiomics analysis of matched ER+ primary and recurrent breast cancers on or after adjuvant endocrine therapy
Martinez-Perez C, Kay C, Meehan J, Dixon JM, Turnbull AK. The University of Edinburgh; The University of Edinburgh / Edinburgh Breast Unit.
PD10-10 Single cell characterization of longitudinal biopsies from breast cancer patients treated with the aromatase inhibitors letrozole and exemestane in sequence
Ghannoum S, Steen C, Fongård M, Bjørnstad M, reitsma L, Geisler S, Seyedzadeh M, Buvarp U-C, Loeng M, Lüders T, Lambrechts D, Lyngra M, Kristensen V, Geisler J, Tekpli X. Oslo University Hospital; Akershus University Hospital; Laboratory of Translational Genetics, VIB Center for Cancer Biology, KU Leuven, Leuven; University of Oslo, Norway.